Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma
- 2 January 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (1) , 5-15
Abstract
: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (a...Keywords
Funding Information
- National Cancer Institute
This publication has 105 references indexed in Scilit:
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- The promise of chimeric antigen receptor T cells (CARTs) in leukaemiaBritish Journal of Haematology, 2016
- Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasmsLeukemia, 2016
- Toxicities of chimeric antigen receptor T cells: recognition and managementBlood, 2016
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discovery, 2016
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Multiple Roles for Astrocytes as Effectors of Cytokines and Inflammatory MediatorsThe Neuroscientist, 2013
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86Nature Immunology, 2004
- Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrierJournal of Neuroimmunology, 1994